Evidence map›Paper›PMID 41656453›Full record

ReviewClinical pharmacokinetics2026

Methodologies for Population Pharmacokinetic Modeling of Target-Site Drug Exposure: A Narrative Review of Current Strategies.

Michelle Mehciz, Pascale C S Rietveld, Birgit C P Koch, Tim Preijers

Abstract readReview
In one paragraph

Review in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michelle MehcizDepartment of Clinical Pharmacy, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0009-0007-8060-2966
Pascale C S RietveldDepartment of Clinical Pharmacy, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0009-0001-6039-8458
Birgit C P KochDepartment of Clinical Pharmacy, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-1202-3643
Tim PreijersDepartment of Clinical Pharmacy, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands. t.preijers@erasmusmc.nl.ORCID 0000-0001-6953-0358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Model-informed precision dosing (MIPD) is increasingly used to guide drug dosing based on population pharmacokinetic (popPK) models developed mainly using plasma concentration data. However, plasma levels may not always correlate well with drug concentrations at the site of action, potentially leading to under- or overestimation of target-site exposure. It is, therefore, important to evaluate which popPK modeling approaches effectively describe drug concentrations at target sites other than plasma to support the selection and implementation of appropriate modeling techniques. This review outlines four general modeling strategies described in literature characterizing the relationship between plasma and target-site drug concentrations. The first approach includes rate constants describing inflow and outflow, which is especially useful for unidirectional transport or large flow rate differences. Second, intercompartmental clearance models capture bidirectional transport with a single parameter that is directly comparable with elimination clearance or blood flow. Third, effect compartment models are used to describe delayed tissue distribution. Lastly, the target site can be modeled as part of either the central or the peripheral compartment. Although therapeutic drug monitoring (TDM) based on target-site concentrations has been suggested, implementation is limited by invasive sampling procedures, limited sample volumes, and the lack of established pharmacokinetic/pharmacodynamic targets. Nevertheless, even small differences in target-site exposure can result in clinical implications, and the applicability of drug monitoring using target-site concentrations has been shown in critically ill patients. In conclusion, target-site concentrations have been successfully predicted using different modeling methodologies and have demonstrated potential to optimize therapy in select clinical cases.

Indexed as

Drug MonitoringModels, BiologicalPharmacokineticsHumansPharmaceutical PreparationsTissue DistributionPharmaceutical Preparations

Identifiers

PMID41656453
PMCPMC13038802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.